Septerna Business Summary

Septerna, Inc. (SEPN) is a clinical-stage biopharmaceutical company that generates revenue through strategic R&D collaborations, licensing agreements, and milestone-based payments, most notably a $2 billion partnership with Novo Nordisk for oral metabolic therapies. The company leverages its proprietary Native Complex Platform to engineer oral small-molecule drugs targeting G protein-coupled receptors (GPCRs), focusing on three primary business segments: endocrinology, immunology/inflammation, and metabolic diseases. By utilizing biochemical and computational approaches to stabilize GPCRs in their native signaling states, Septerna aims to unlock previously "undruggable" targets. Within the competitive landscape, the company vies for market share against clinical-stage peers like CRISPR Therapeutics, Immunovant, and TG Therapeutics, distinguishing itself through its platform-centric ability to convert injectable biologics into patient-friendly oral alternatives. The company was established by a high-pedigree founding team including CEO Jeffrey Finer, M.D., Ph.D. (formerly of Third Rock Ventures), and Nobel Laureate Robert Lefkowitz, M.D., alongside GPCR pioneers Arthur Christopoulos and Patrick Sexton. The current leadership suite features President and COO Elizabeth Bhatt, CFO Gil Labrucherie, and Chief Legal Officer Mark A. Wilson, an industry veteran appointed in early 2026 to oversee intellectual property and corporate governance. Septerna’s growth is supported by prominent investors such as Third Rock Ventures, Samsara BioCapital, and RA Capital Management. The Board of Directors, chaired by Jeffrey Tong, was further strengthened in late 2025 by the addition of Keith Gottesdiener, former CEO of Prime Medicine, ensuring deep clinical and regulatory expertise as the company advances its lead candidate, SEP-631, through Phase 1 trials.